A senior GTM Operating Partner audits, coaches, and installs the GTM discipline portfolio companies need before they scale.


![[background image] image of a modern office space (for a ai healthcare company)](https://cdn.prod.website-files.com/6984c977590309206c325bea/69d3fefa2e3ddfb53d1414d1_heatmap.png)

Without a common model, portfolio support becomes uneven. Tyos brings one operating framework, clear stage gates, and stronger execution discipline across the portfolio.
![[interface]](https://cdn.prod.website-files.com/6984c977590309206c325bea/69d40125c2859cc750830e7b_performance%205.png)
Tyos gives GPs a clearer view of each company’s commercial progress, from strategic focus to sales readiness.

Commercial risk often sits below the surface. Tyos helps assess GTM foundations before investment and identify the work needed after close.

Every portfolio company moves through the same five-stage model, giving founders a clearer path to execution and investors a consistent way to track progress.
A 60-point GTM scorecard combined with a founder self-assessment.
It surfaces the real gaps, not just the visible ones.
A prioritised GTM plan focused on the few levers that matter most.
It clarifies what to stop, what to build first, and what progress should look like.
A company-specific GTM playbook covering key gates, deliverables, and dependencies.
It becomes the execution backbone for the team.
Twice-monthly reviews, ongoing feedback, and written investor summaries.
Each company is supported by a named Tyos operating partner, tracking progress over time.
Coaching compounds into a proprietary, AI-powered GTM stack, built with the company's team. The output is a system the company owns and keeps improving — not a dependency on outside help.
A portfolio-wide GTM operating model
Portfolio companies that build and own a proprietary, AI-powered GTM stack
A consistent view of commercial progress by company
A repeatable operating cadence across the fund
Better support decisions and earlier visibility on risk
GTM discipline that compounds across the portfolio